In a study of malignant melanoma (Dahan et al., 2015), knocking out the Fcγ receptor (FcγR) in mice enhanced the anti-tumor effect of the anti-PD-1 antibody, directly showing a correlation between FcγR and ICIs. Here, FCGR2A is linked to neoplasm.